Acute Lymphoblastic Leukemia Clinical Trial
Official title:
A Phase I Study of Sirolimus With PEG-Asparaginase in Multiple Recurrent or Refractory Childhood Acute Lymphoblastic Leukemia
Verified date | November 2012 |
Source | Emory University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The goal of this study is to find a safe dose of sirolimus that can be used with a standard
dose of L-asparaginase. To find the safe dose, the investigators will give the first patient
a very small dose of sirolimus (smaller than the dose used in organ transplant children) and
the standard dose of L-asparaginase. The investigators will then look for side effects. If
side effects develop, the investigators will decrease the dose of sirolimus. If they do not,
the investigators will increase the dose of sirolimus in the next patient on the study. The
investigators will continue this method until fewer than one-third of patients have a side
effect that would require stopping the drug or changing the dose.
The investigators plan to enroll up to 15 children with relapsed ALL. The enrolled patients
must have recovered from other treatment before starting this study. Also, they cannot have
severe side effects from their earlier therapy that will possibly make these drugs less
safe.
The investigators will collect information on whether these drugs help to cure the ALL, but
the purpose will be to find a dose of sirolimus that does not cause too many side effects
when combined with L-asparaginase. This will be explained to the families and they will sign
a written consent. The patients will provide either verbal or written assent when
appropriate.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | August 2012 |
Est. primary completion date | August 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A to 21 Years |
Eligibility |
Inclusion Criteria: 1. Less than 21 years old. 2. Acute lymphoblastic leukemia. 3. Second or greater bone marrow relapse or 1st relapse and refractory to at least 2 Attempts at re-induction. 4. Life expectancy of at least 8 weeks. 5. Fully recovered from the acute toxic effects of all prior therapy. 6. Appropriate organ function. Exclusion Criteria: 1. Patients with a documented history of = grade 3 local or systemic reactions to PEG-asparaginase. 2. Patients with a documented history of anti-E. coli asparaginase antibodies. 3. Patients with a history of = grade 3 pancreatitis. 4. Patients with an active and uncontrolled infection. 5. Patients s/p allogeneic bone marrow transplantation, who are still on immunosuppressants. 6. Pregnant or lactating females. Women of childbearing age will agree to use contraception during the protocol. 7. Patients currently receiving other investigational agents, medications, or supplements with a known anti-leukemic effect. 8. Other concomitant medications that may alter the metabolism of Sirolimus (See section 7.2). 9. Patients who, in the opinion of the investigator, will not be able to comply with safety monitoring requirements of the study. 10. Patients with a history of a documented thrombus from previous asparaginase therapy. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Children's Healthcare of Atlanta | Atlanta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Emory University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To estimate the maximum tolerated dose (MTD) of sirolimus in children with refractory or recurrent acute lymphoblastic leukemia (ALL) who are concurrently receiving PEG-asparaginase. | end of study | Yes | |
Primary | To determine the dose limiting toxicities of sirolimus in combination with PEG-asparaginase in this Phase I Study. | end of study | Yes | |
Secondary | To use phospho-flow to measure the degree of phosphorylation of signaling pathway proteins in response to specific stimulating events in bone marrow derived leukemia cells obtained at the time of study entry and at day 15 and 29. | end of study | No | |
Secondary | To correlate the signal pathway phosphorylation to clinical response to the chemotherapy regimen used in this study. | end of study | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT05772000 -
Clinical Significance of Occult Central Nervous System Localization
|
||
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT03114865 -
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06308588 -
Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
|
Phase 2 | |
Recruiting |
NCT05579132 -
A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT02231853 -
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 | |
Recruiting |
NCT06195891 -
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Withdrawn |
NCT02815059 -
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
|
Phase 1 | |
Completed |
NCT00390793 -
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A | |
Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Not yet recruiting |
NCT06350994 -
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
|
||
Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
Not yet recruiting |
NCT04488237 -
Vitamin D and Methotrexate Adverse Effects
|
||
Completed |
NCT02544438 -
Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 |